Literature DB >> 24522268

Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer.

Shogo Hatanaka1, Seiichi Tamaki2, Haruna Endo3, Norifumi Mizuno3, Naoki Nakamura3.   

Abstract

Volumetric-modulated arc therapy (VMAT) is a widespread intensity-modulated radiation therapy (IMRT) method, however, VMAT requires adaptation of the radiation treatment planning system (RTPS) and linear accelerator (linac); these upgrades are quite expensive. The Smart Arc of Pinnacle(3) (Philips), which is the software used in VMAT calculations, can select constant dose rate (CDR) mode. This approach has a low initial cost because the linac upgrade is not required. The objective of this study was to clarify the utility of CDR mode for prostate IMRT. Pinnacle(3) and Clinac 21EX linac (Varian, 10 MV X-rays) were used for planning. The plans were created for 28 patients using a fixed multi-field IMRT (f-IMRT), VMAT and CDR techniques. The dose distribution results were classified into three groups: optimal, suboptimal and reject. For the f-IMRT, VMAT and CDR results, 25, 26 and 21 patients were classified as 'optimal', respectively. Our results show a significant reduction in the achievement rate of 'optimal' for a CDR when the bladder volume is <100 cm(3). The total numbers of monitoring units (MUs) (average ± 1σ) were 469 ± 53, 357 ± 35 and 365 ± 33; the average optimization times were ∼50 min, 2 h and 2 h 40 min, and the irradiation times were ∼280 s, 60 s and 110 s, respectively. CDR can reduce the total MUs and irradiation time compared with f-IMRT, and CDR has a lower initial cost compared with VMAT. Thus, for institutions that do not currently perform VMAT, CDR is a useful option. Additionally, in the context of patient identification, bladder volume may be useful.
© The Author 2014. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  Smart Arc CDR; constant dose rate; intensity-modulated radiation therapy; prostate cancer; volumetric-modulated arc therapy

Mesh:

Year:  2014        PMID: 24522268      PMCID: PMC4099990          DOI: 10.1093/jrr/rrt232

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


INTRODUCTION

Intensity-modulated radiation therapy (IMRT) is a technology that delivers radiation more precisely to the tumor than earlier techniques, sparing the surrounding normal tissue from unnecessary exposure [1]. However, the required irradiation time is longer and the total number of monitoring units (MUs) is greater for fixed multi-field IMRT (f-IMRT) compared with conventional methods [1]. The increased irradiation time may increase the intrafractional error and the patient restriction time; additionally, an increase in the total number of MUs may cause problems with radiation shielding [2]. More recently, volumetric-modulated arc therapy (VMAT), a widespread rotational IMRT method using a dynamic gantry speed and multileaf collimator (MLC) field shape, has gained considerable attention [3]. The dose–volume histograms (DVHs) of VMAT and that of f-IMRT are equivalent; however, the total number of MUs and required irradiation time are less for VMAT than for f-IMRT [4, 5]. To use the VMAT approach, the hardware and software systems of the radiation treatment planning system (RTPS), as well as the linear accelerator (linac), must be upgraded; these upgrades are costly. Thus, many institutions do not have the means to perform VMAT and must continue with the problems specified above. The Smart Arc system of Pinnacle3 (RTPS by Philips) software used for rotational IMRT calculations, can select VMAT mode or constant-dose-rate (CDR) mode. Details of the SmartArc planning algorithm have been described by Bzdusek et al. [6]. CDR mode is a rotational IMRT technique that uses a fixed gantry rotational speed and a fixed dose rate. Compared with f-IMRT, the potential advantages of CDR include a large reduction in irradiation time and in the total number of MUs [5]. Moreover, the system can be used by institutions that cannot perform VMAT (because the linac upgrade is not required for CDR mode). Therefore, such institutions can reduce both the required irradiation time and the total number of MUs to make the initial cost low. For institutions that do not currently perform VMAT, CDR may be a useful option. The objective of this study was to clarify the utility of Smart Arc CDR for prostate IMRT. We expected that achieving the defined dose limit with CDR may be more difficult than with VMAT. Of the two approaches, VMAT has more parameters that can be adjusted for optimization. The second objective of this study was to identify the subgroup of patients in whom CDR cannot achieve the optimal dose distribution.

MATERIALS AND METHODS

Pinnacle3 version 9.2 was used as the RTPS in this study. The linac model (Clinac 21EX, Varian; X-ray energy: 10 MV) was used for planning. The plans were created using f-IMRT with the direct machine parameter optimization [7], VMAT and CDR techniques for 28 patients (average age: 75 years; range: 59–88 years) based on computed tomography (CT) images of their prostate cancer. Optimization was carried out using an inverse planning technique. Details of these methods are provided below.

Planning CT

A LightSpeed RT16 (GE) was used for the planning CT. Body-fix (Medical Intelligence) and supine set-ups were used to keep the patients stationary. CT images were acquired in 2.5-mm slice thicknesses. The procedure to acquire the CT images is described below. Patients ingested 350-mg magnesium oxide tablets 2 d before CT-image acquisition at a dose rate of three tablets per day. CT images were acquired after 10:00 AM. Patients were instructed to drink a fixed volume of water 60–90 min before CT image acquisition; urination was prohibited to enable acquisition of the CT image. The CT image was examined for gas in the rectum by the radiation oncologist after image acquisition. If needed, additional CT images were acquired based on the recommendation that the diameter of the rectum, transversely at the base, was > 4 cm [8].

Contours

The patients were classified into the following four groups according to the National Comprehensive Cancer Network (NCCN) [9] criteria: ‘low risk’ (T1–T2a, Gleason score 2–6 and PSA < 10 ng/ml), ‘intermediate risk’ (T2b–T2c or Gleason score 7 or PSA 10–20 ng/ml), ‘high risk’ (T3a or Gleason score 8–10 or PSA > 20 ng/ml), and ‘very high risk’ (T3b–T4). The target volume was determined based on the risk group. There were 3 low risk patients, 16 intermediate risk patients, 9 high risk patients, and no very high risk patients in this study.

Clinical target volume

The clinical target volume (CTV) for the ‘low risk group’ was the prostate only, for the ‘intermediate risk group’ was the prostate + seminal vesicle surrounding 1 cm of the prostate, for the ‘high risk group’ was the prostate + seminal vesicle surrounding 2 cm of the prostate, with prostate+5-mm margin (T3a), and for the ‘very high risk group’ the prostate + seminal vesicle (T3b), prostate + 5-mm margin + seminal vesicle surrounding 2 cm of the prostate (T4).

Planning target volume

The planning target volume (PTV) was defined by the CTV + 10-mm margin (rectum side: 6 mm).

Organ at risk

The rectum (from the ischial tuberosities to the rectosigmoid flexure), the whole bladder, the small intestine surrounding 1.5 cm of the PTV, the sigmoid colon surrounding 1.5 cm of the PTV, and the femoral heads and body were defined as the organs at risk (OARs).

Optimization and plan evaluation

Table 1 shows the characteristics and planning conditions of f-IMRT, CDR and VMAT. f-IMRT was planned using seven beams; VMAT and CDR were planned using a single arc. The prescribed dose to 95% (D95) of the PTV was 74 Gy in 37 fractions. The dose calculation grid size was set to 2 mm for all examples in this study. The isocenter was set to the PTV center. Adaptive Convolve [10] with heterogeneous correction was used for the dose calculation algorithm.
Table 1.

Characteristics and planning conditions of f-IMRT, CDR and VMAT

f-IMRTVMATCDR
IMRT techniqueStatic MLCDynamic MLC (Rotational)Dynamic MLC (Rotational)
Gantry rotation speedVariableFixed
Dose rateFixedVariableFixed
Gantry angle (degrees)0, 50, 100, 155, 205, 260, 310230–130 (CW)230–130 (CW)
Calculation pitch (degrees)44
Devices that must be upgraded (on the assumption that f-IMRT can be carried out)RTP and LinacRTP
Characteristics and planning conditions of f-IMRT, CDR and VMAT Optimized plans were evaluated with respect to dose distribution, total number of MUs, optimization time and irradiation time. The dose distributions were evaluated with respect to the DVH and the dose limit defined for this study. The dose distribution results were classified into three groups: optimal, suboptimal and reject, based on the achievement level of the dose limit. Table 2 shows the dose limit used. The optimization time corresponds to the time taken to optimize the plan with the RTPS. As a consequence of the difficulties presented by some patients in achieving the appropriate dose limit using CDR, the chi-square test and t-test were used for verification of the correlation between the level of achievement of the dose limit and the organ volume obtained with planning CT. Positioning of the small intestine and sigmoid colon close to the PTV might make achievement of the dose limit problematic. Additionally, a bladder volume of 100–150 cm3 is more suitable for planning CT acquisition and irradiation [11]. Therefore, a bladder volume of 100 cm3 was used as an index of verification of the level of achievement of the dose limit in this study. The chi-square test was carried out to verify the correlations between the achievement rate of the dose limit and the bladder volume and positions of the small intestine and sigmoid colon. SPSS version 17 (IBM) was used for statistical analysis.
Table 2.

Dose limits used in this study

OptimalSuboptimal
PTVD95 (D94–D96)74 Gy
Mean<77.7 Gy<79.2 Gy
Maximum<81.4 Gy<85.1 Gy
D98>70.3 Gy
V75<5%< 10%
V70<20%<25%
RectumV60<40%<45%
V50<50%<50%
V40<65%
Maximum<78 Gy<82 Gy
BladderV70<30%<35%
V50<50%<60%
Femoral headsMaximum<50 GyD5 < 50 Gy
Small intestineMaximum<60 Gy
Sigmoid colonMaximum<65 Gy
BodyMaximum<81.4 Gy<85.1 Gy
Dose limits used in this study

RESULTS

DVH and the achievement rate of the dose limit

Figures 1–3 display the average DVH for 28 patients of the PTV, rectum and bladder. Table 3 lists the dose indexes of the PTV, rectum and bladder, which are the average of all cases. The DVHs of the PTV for all of the methods were in good agreement, and D2, D50 and D95 were within 0.5 Gy. D2 of the rectum and bladder for all methods were within 0.5 Gy, and the volume receiving 50–70 Gy (V50–V70) were within 3%. The V20–V40 using the CDR approach was ∼5% higher than with the f-IMRT and VMAT methods. The achievement level of the dose limit is evident for the f-IMRT, VMAT and CDR techniques. There were no ‘rejects’; 25 (89%), 26 (93%) and 21 (75%) patients were classified as ‘optimal’ and the remaining patients were classified as ‘suboptimal’ (f-IMRT, VMAT and CDR, respectively). The optimal CDR achievement rate was slightly lower than those of the other two methods. Tables 4 and 5 reveal the correlation between the achievement level of the dose limit and the risk group or organ volume. Our results indicate a significant reduction in the dose limit achievement rate for the CDR method when the bladder volume was <100 cm3.
Fig. 1.

Comparison of the PTV DVH of the CDR, f-IMRT and VMAT techniques as a function of dose. The results were in good agreement.

Fig. 3.

Bladder DVH using the CDR, f-IMRT and VMAT techniques. The V20–V40 of the bladder determined using CDR was higher than that obtained with the other two methods.

Table 3.

Dose indexes of the PTV, rectum and bladder (average ± 1σ of all cases)

Dose indexCDRf-IMRTVMAT
PTVD95 (Gy)74.10 ± 0.2974.30 ± 0.1974.20 ± 0.17
D50 (Gy)76.85 ± 0.4576.45 ± 0.4576.55 ± 0.60
D2 (Gy)79.95 ± 0.5179.70 ± 0.4879.80 ± 0.98
RectumD2 (Gy)76.40 ± 0.4976.05 ± 0.6775.95 ± 0.44
V70 (%)18.0 ± 2.316.8 ± 2.717.9 ± 1.9
V60 (%)30.3 ± 4.429.1 ± 4.130.0 ± 4.5
V50 (%)40.2 ± 5.837.6 ± 5.639.2 ± 6.2
BladderD2 (Gy)76.85 ± 0.4776.60 ± 0.6376.65 ± 0.41
V70 (%)25.4 ± 4.825.5 ± 4.925.6 ± 4.8
V60 (%)35.0 ± 5.934.3 ± 6.734.8 ± 6.0
V50 (%)43.6 ± 7.342.2 ± 8.142.2 ± 7.3
Table 4.

Results of the t-test for verification of the correlation between the level of achievement of the dose limit and organ volume obtained with planning CT

VariableAverage (Range)P
Prostate volume30.6 (6.3–71.9) cm30.776
PTV volume142.9 (71.6–212.1) cm30.643
Rectum volume51.7 (33.4–107.9) cm30.719
Bladder volume159.6 (69.6–386.4) cm30.148
Table 5.

Results of the chi-square test for verification of the correlations between the achievement rate of the dose limit and risk group, the bladder volume and the positions of the small intestine and sigmoid colon

VariableOptimalP
Risk groupLow (3)Intermediate (16)High (9) 1/314/16 6/90.108
Bladder volume<=100 cm3 (9) >100 cm3 (19) 4/917/190.020
Sigmoid colon surrounding 1.5 cm of PTV?Yes (19)No (9)13/19 8/90.371
Small intestine surrounding 1.5 cm of PTV?Yes (9)No (19) 7/914/191.000
Dose indexes of the PTV, rectum and bladder (average ± 1σ of all cases) Results of the t-test for verification of the correlation between the level of achievement of the dose limit and organ volume obtained with planning CT Results of the chi-square test for verification of the correlations between the achievement rate of the dose limit and risk group, the bladder volume and the positions of the small intestine and sigmoid colon Comparison of the PTV DVH of the CDR, f-IMRT and VMAT techniques as a function of dose. The results were in good agreement. Rectum DVH using the CDR, f-IMRT and VMAT techniques. The V20–V40 of the rectum determined by CDR was higher than that obtained with the other two methods. Bladder DVH using the CDR, f-IMRT and VMAT techniques. The V20–V40 of the bladder determined using CDR was higher than that obtained with the other two methods.

Total MU, optimization time and irradiation time

Figures 4–6 display the total number of MUs, the optimization time, and the irradiation time, respectively. For the f-IMRT, VMAT and CDR methods, the total numbers of MUs (average ± 1σ) were 469 ± 53, 357 ± 35 and 365 ± 33, respectively; the optimization times were ∼50 min, 2 h and 2 h 40 min, respectively; and the irradiation times were ∼280 s, 60 s and 110 s, respectively. For f-IMRT, the beam loading time for each field and the time between each segment could not be calculated accurately because this method used a step-and-shoot approach. Therefore, the irradiation times for f-IMRT were acquired using a stopwatch.
Fig. 4.

Total numbers of MUs determined using the f-IMRT, CDR and VMAT techniques. The f-IMRT technique exhibited the largest total number of MUs.

Fig. 6.

Irradiation times for the f-IMRT, CDR and VMAT techniques. f-IMRT required the longest irradiation time.

Total numbers of MUs determined using the f-IMRT, CDR and VMAT techniques. The f-IMRT technique exhibited the largest total number of MUs. Optimization times of the f-IMRT, CDR and VMAT techniques. The optimization time for CDR was the longest. Irradiation times for the f-IMRT, CDR and VMAT techniques. f-IMRT required the longest irradiation time.

DISCUSSION

As our results indicate, the optimal CDR achievement rate was slightly lower than that of the other two methods. It has been reported that the DVHs of VMAT and f-IMRT are equivalent [4, 5]. However, the CDR technique offers fewer parameters that can be optimized compared with VMAT. Therefore, it is more difficult to achieve the defined dose limit with CDR than with VMAT. Moreover, it becomes increasingly difficult to achieve the dose limit when the bladder volume during planning CT is <100 cm3. This suggests that if the bladder volume is >100 cm3, it may be possible to improve the achievement rate of the dose limit for CDR. Additionally, it has been reported that a bladder volume of 100–150 cm3 is adequate for planning [11]; thus, levels closer to 100 cm3 appear to be reasonable in practice. Figures 2–3 reveal that V20–V40 of the rectum and bladder for CDR was higher than that for f-IMRT and VMAT. V20–V40 of the rectum and bladder may not be related to an increased incidence of adverse events [12] . Therefore, our results indicated that the dose distribution and DVH of the CDR, f-IMRT and VMAT methods were equivalent clinically. The total number of MUs for the CDR and VMAT methods were almost equal and <20–25% of that of f-IMRT. Additionally, the required irradiation time for CDR was <60% of that of f-IMRT. CDR also offered improved throughput and a reduced intrafractional error compared with f-IMRT. However, the required irradiation time of CDR was longer by ∼50 s compared with that of VMAT; this was attributed to the fixed gantry rotational speed and dose rate of the CDR technique (i.e. these two parameters could not be optimized). The optimization time of CDR was ∼3 times that of f-IMRT because CDR was calculated by each 4° increment of gantry angle (large number of fields). VMAT was also calculated using a number of fields, however, the optimization time of CDR was longer than that of VMAT. This result was attributed to the numerous iterations required with IMRT planning using CDR to achieve the dose limit. Compared with f-IMRT, the potential advantages of CDR include a large reduction in irradiation time and in the total number of MUs, however, the optimization time of CDR is longer than that of f-IMRT. Therefore, for institutions using CDR for patients who can reach the dose limit easily, it may be reasonable to use f-IMRT for those who cannot. Additionally, the bladder volume may be useful for identifying into which category a patient falls in order to determine the appropriate treatment.

CONCLUSION

The utility of Smart Arc CDR for prostate IMRT was clarified in this study. CDR can reduce the total number of MUs and the patient irradiation time compared with f-IMRT, resulting in a lower initial cost compared with that of VMAT. For institutions that do not have the means to perform VMAT, CDR can be used instead. Identifying which patients will have difficulty in achieving the dose limit in advance is important. Bladder volume may be a useful index for determining this patient subset, and for these patients a combination of CDR and f-IMRT should provide a better outcome.
  10 in total

1.  Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors.

Authors:  A Pirzkall; M Carol; F Lohr; A Höss; M Wannenmacher; J Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

2.  The relationship between the bladder volume and optimal treatment planning in definitive radiotherapy for localized prostate cancer.

Authors:  Naoki Nakamura; Naoto Shikama; Osamu Takahashi; Kenji Sekiguchi; Yukihiro Hama; Keiko Akahane; Keiichi Nakagawa
Journal:  Acta Oncol       Date:  2011-12-01       Impact factor: 4.089

3.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

4.  Development and evaluation of an efficient approach to volumetric arc therapy planning.

Authors:  Karl Bzdusek; Henrik Friberger; Kjell Eriksson; Björn Hårdemark; David Robinson; Michael Kaus
Journal:  Med Phys       Date:  2009-06       Impact factor: 4.071

5.  Collapsed cone convolution of radiant energy for photon dose calculation in heterogeneous media.

Authors:  A Ahnesjö
Journal:  Med Phys       Date:  1989 Jul-Aug       Impact factor: 4.071

Review 6.  Radiation dose-volume effects in radiation-induced rectal injury.

Authors:  Jeff M Michalski; Hiram Gay; Andrew Jackson; Susan L Tucker; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

7.  Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.

Authors:  Renaud de Crevoisier; Susan L Tucker; Lei Dong; Radhe Mohan; Rex Cheung; James D Cox; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

8.  A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis.

Authors:  Jeremy D Ruben; Craig M Lancaster; Phillip Jones; Ryan L Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

9.  Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.

Authors:  David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

10.  Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases.

Authors:  Pengpeng Zhang; Laura Happersett; Margie Hunt; Andrew Jackson; Michael Zelefsky; Gig Mageras
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

  10 in total
  3 in total

1.  Is volumetric modulated arc therapy with constant dose rate a valid option in radiation therapy for head and neck cancer patients?

Authors:  Annamaria Didona; Valentina Lancellotta; Claudio Zucchetti; Bianca Moira Panizza; Alessandro Frattegiani; Martina Iacco; Anna Concetta Di Pilato; Simonetta Saldi; Cynthia Aristei
Journal:  Rep Pract Oncol Radiother       Date:  2018-03-19

2.  Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients.

Authors:  Wenliang Yu; Haijiao Shang; Congying Xie; Ce Han; Jinling Yi; Yongqiang Zhou; Xiance Jin
Journal:  Radiat Oncol       Date:  2014-11-04       Impact factor: 3.481

3.  Assessment of Volumetric-Modulated Arc Therapy for Constant and Variable Dose Rates.

Authors:  Mariluz De Ornelas-Couto; Ivaylo Mihaylov; Nesrin Dogan
Journal:  J Med Phys       Date:  2017 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.